Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The companyâs lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health. Source
No articles found.
Pawprint is an app that allows you to streamline communication between veterinaria...
Pawprint is an app that allows you to streamlin...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeu...
Magenta Therapeutics is a clinical-stage biotec...
BASi provides drug discovery and development services and analytical instruments t...
BASi provides drug discovery and development se...
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...
Cancer Genetics, Inc. is an emerging leader in ...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Radius is a science-driven fully integrated biopharmaceutical company that is comm...
Radius is a science-driven fully integrated bio...
Join the National Investor Network and get the latest information with your interests in mind.